Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Switching From Lopinavir/Ritonavir Plus Tenofovir and Emtricitabine (or Lamivudine) to Darunavir (Prezista) and Raltegravir to Evaluate Renal Function

NCT01294761 is registered in ClinicalTrials.gov with National Center for Global Health and Medicine, Japan as lead sponsor.

NCT NCT01294761
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01294761 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Switching From Lopinavir/Ritonavir Plus Tenofovir and Emtricitabine (or Lamivudine) to Darunavir (Prezista) and Raltegravir to Evaluate Renal Function
Lead sponsor
National Center for Global Health and Medicine, Japan
Phase
Not applicable
Overall status
Completed
Start date
February 28, 2011
Completion date
December 31, 2013
Enrollment
59 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections